Literature DB >> 9661227

Group treatment for smoking cessation among persons with schizophrenia.

J Addington1.   

Abstract

People with schizophrenia smoke more than the general population and more than other psychiatric diagnostic groups. The rate of smoking in the general population is 30 percent, and reported rates for people with schizophrenia range between 62 percent and 81 percent. The author briefly reviews evidence that nicotine's augmentation of dopamine release may account for the high prevalence of smoking in this group. The affective, cognitive, and social difficulties and the symptoms experienced by many patients with schizophrenia indicate that existing smoking cessation programs may not be appropriate for them. The author describes three programs developed for use with this population and reviews evidence of their effectiveness. Preliminary evidence suggests that transdermal nicotine patches are effective and that patients do not misuse them. The author concludes that stopping smoking is possible for individuals with schizophrenia, especially if the treatment is specifically designed for them.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661227     DOI: 10.1176/ps.49.7.925

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  16 in total

1.  A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients.

Authors:  Hsing-Kang Chen; Tsuo-Hung Lan; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-23       Impact factor: 5.270

2.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

Review 3.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

4.  Effects of a tobacco ban on long-term psychiatric patients.

Authors:  Grant T Harris; Daniel Parle; Joseph Gagné
Journal:  J Behav Health Serv Res       Date:  2006-12-19       Impact factor: 1.505

Review 5.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

6.  Open-Label Study of Craving in Smokers With Schizophrenia Using Nicotine Nasal Spray Compared to Nicotine Patch.

Authors:  Jill M Williams; Kunal K Gandhi; Maria Katsamanis Karavidas; Marc L Steinberg; Shou-En Lu; Jonathan Foulds
Journal:  J Dual Diagn       Date:  2008-10-01

Review 7.  Use of smoking cessation therapies in individuals with psychiatric illness : an update for prescribers.

Authors:  Stephen Kisely; Leslie Anne Campbell
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings.

Authors:  Sharon M Hall; Judith J Prochaska
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

9.  Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia.

Authors:  Kuan-Ju Chou; Hsing-Kang Chen; Chih-Hung Hung; Tzu-Ting Chen; Chun-Ming Chen; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-07-09       Impact factor: 5.270

Review 10.  Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.